As low as $25 copay with manufacturer coupon for eligible commercial patients on qualifying dose
Semaglutide is a glucagon-like peptide-1 receptor agonist
(Rezdiffra, in comparison, costs around $4,000 per month.) Many private insurers, state Medicaid programs and Medicare do not cover these medications for weight loss alone, though the added indication for MASH could potentially expand access
The gut moves slower, and more water is absorbed from the stool, creating hard, difficult-to-pass impactions
Each of these treatments, through distinct pathways and mechanisms, provides pivotal options for patients dealing with the complexities of diabetes and weight management, reflecting the growing precision and personalization in medical care